Zebrafish as a preclinical in vivo screening model for nanomedicines

Published on Jan 4, 2019in Advanced Drug Delivery Reviews13.3
· DOI :10.1016/J.ADDR.2019.01.001
Sandro Sieber9
Estimated H-index: 9
(University of Basel),
Philip Grossen8
Estimated H-index: 8
(University of Basel)
+ 4 AuthorsJörg Huwyler49
Estimated H-index: 49
(University of Basel)
Abstract The interactions of nanomedicines with biological environments is heavily influenced by their physicochemical properties. Formulation design and optimization are therefore key steps towards successful nanomedicine development. Unfortunately, detailed assessment of nanomedicine formulations, at a macromolecular level, in rodents is severely limited by the restricted imaging possibilities within these animals. Moreover, rodent in vivo studies are time consuming and expensive, limiting the number of formulations that can be practically assessed in any one study. Consequently, screening and optimisation of nanomedicine formulations is most commonly performed in surrogate biological model systems, such as human-derived cell cultures. However, despite the time and cost advantages of classical in vitro models, these artificial systems fail to reflect and mimic the complex biological situation a nanomedicine will encounter in vivo. This has acutely hampered the selection of potentially successful nanomedicines for subsequent rodent in vivo studies. Recently, zebrafish have emerged as a promising in vivo model, within nanomedicine development pipelines, by offering opportunities to quickly screen nanomedicines under in vivo conditions and in a cost-effective manner so as to bridge the current gap between in vitro and rodent studies. In this review, we outline several advantageous features of the zebrafish model, such as biological conservation, imaging modalities, availability of genetic tools and disease models, as well as their various applications in nanomedicine development. Critical experimental parameters are discussed and the most beneficial applications of the zebrafish model, in the context of nanomedicine development, are highlighted.
📖 Papers frequently viewed together
41 Citations
201814.59ACS Nano
77 Citations
58 Citations
#1Dominik Witzigmann (UBC: University of British Columbia)H-Index: 16
#2Sjoerd Hak (NTNU: Norwegian University of Science and Technology)H-Index: 15
Last. Roy van der Meel (UBC: University of British Columbia)H-Index: 21
view all 3 authors...
9 CitationsSource
#1Fabiola Porta (University of Basel)H-Index: 9
#2Daniel Ehrsam (University of Basel)H-Index: 2
Last. Henriette E. Meyer zu Schwabedissen (University of Basel)H-Index: 31
view all 4 authors...
Cytotoxic compounds used to treat cancer are often associated with adverse events. The development of formulations activated by tumor-specific triggers would allow a reduction of systemic exposure while maintaining therapeutic concentrations in the tumor. One enzyme with proteolytic activity reported to be involved in tumor progression and assumed to be enhanced in the tumor environment is the matrix metalloproteinase 9 (MMP-9). In our study, we aimed to develop surface-modified PDMS–PMOXA polym...
7 CitationsSource
#1M. Juliana Gomez-Garcia (U of C: University of Calgary)H-Index: 4
#2Amber L. Doiron (U of C: University of Calgary)H-Index: 11
Last. Kristina D. Rinker (U of C: University of Calgary)H-Index: 16
view all 10 authors...
Nanoparticles in the bloodstream are subjected to complex fluid forces as they move through the curves and branches of healthy or tumor vasculature. While nanoparticles are known to preferentially accumulate in angiogenic vessels, little is known about the flow conditions in these vessels and how these conditions may influence localization. Here, we report a methodology which combines confocal imaging of nanoparticle-injected transgenic zebrafish embryos, 3D modeling of the vasculature, particle...
26 CitationsSource
#1Federico Fenaroli (University of Oslo)H-Index: 12
#2Urska Repnik (University of Oslo)H-Index: 32
Last. Gareth Griffiths (University of Oslo)H-Index: 94
view all 15 authors...
The enhanced permeability and retention (EPR) effect is the only described mechanism enabling nanoparticles (NPs) flowing in blood to reach tumors by a passive targeting mechanism. Here, using the transparent zebrafish model infected with Mycobacterium marinum we show that an EPR-like process also occurs allowing different types of NPs to extravasate from the vasculature to reach granulomas that assemble during tuberculosis (TB) infection. PEGylated liposomes and other NP types cross endothelial...
37 CitationsSource
#1Marieke Poß (KIT: Karlsruhe Institute of Technology)H-Index: 5
#2Eva Zittel (KIT: Karlsruhe Institute of Technology)H-Index: 4
Last. Claus Feldmann (KIT: Karlsruhe Institute of Technology)H-Index: 58
view all 7 authors...
13 CitationsSource
#1Enamul Haque (Deakin University)H-Index: 26
#2Alister C. Ward (Deakin University)H-Index: 56
Nanoparticles are increasingly being developed for in vivo use, from targeted drug delivery to diagnostics, where they have enormous potential, while they are also being used for a variety of applications that can result in environmental exposure for humans. Understanding how specific nanoparticles interact with cells and cell systems is essential to gauge their safety with respect to either clinical or environmental exposure. Zebrafish is being increasingly employed as a model to evaluate nanop...
58 CitationsSource
#1Gheyath K. Nasrallah (Qatar University)H-Index: 27
#2Yu Zhang (Fudan University)H-Index: 27
Last. Yonghui Deng (Fudan University)H-Index: 63
view all 9 authors...
Abstract In this work, shearing interface coassembly in biliquid phase systems is employed to synthesize biocompatible core-shell magnetic mesoporous silica microspheres with uniform size of about 600 nm, perpendicular mesopores of 6.0 nm and large pore volume of 0.77 cm3/g. The toxicology assays based on the zebrafish model was conducted to test under a high-throughput manner for the biosafety of Fe3O4@RF@mSiO2 microspheres. The highest no observed toxic effect concentration (NOEC) estimated by...
16 CitationsSource
#1David AdamsH-Index: 20
#1David H. AdamsH-Index: 206
Last. Ole B. Suhr (Umeå University)H-Index: 61
view all 36 authors...
BACKGROUND: Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin.METHODS: In this phase 3 trial, we randomly assigned patients ...
875 CitationsSource
#1Sven H. C. Askes (LEI: Leiden University)H-Index: 16
#2Nelli Bossert (LEI: Leiden University)H-Index: 4
Last. Doris Heinrich (Fraunhofer Society)H-Index: 17
view all 9 authors...
Abstract The long-term fate of biomedical nanoparticles after endocytosis is often only sparsely addressed in vitro and in vivo , while this is a crucial parameter to conclude on their utility. In this study, dual-fluorescent polyisobutylene-polyethylene glycol (PiB-PEG) polymersomes were studied for several days in vitro and in vivo . In order to optically track the vesicles' integrity, one fluorescent probe was located in the membrane and the other in the aqueous interior compartment. These no...
5 CitationsSource
#1Jayesh A. Kulkarni (UBC: University of British Columbia)H-Index: 14
#2Pieter R. Cullis (UBC: University of British Columbia)H-Index: 117
Last. Roy van der Meel (UBC: University of British Columbia)H-Index: 21
view all 3 authors...
Genetic drugs based on RNA or DNA have remarkable therapeutic potential as virtually any disease can be treated by silencing a pathological gene, expressing a beneficial protein, or by editing defective genes. However, therapies based on nucleic acid polymers require sophisticated delivery systems to deliver these macromolecules to the interior of target cells. In this study, we review progress in developing nonviral lipid nanoparticle (LNP) delivery systems that have attractive properties, incl...
126 CitationsSource
Cited By38
#1Aryelle Canedo (UFG: Universidade Federal de Goiás)H-Index: 1
#2Lázaro Wender Oliveira de Jesus (UFAL: Federal University of Alagoas)H-Index: 6
Last. Thiago Lopes Rocha (UFG: Universidade Federal de Goiás)H-Index: 19
view all 0 authors...
Abstract null null Nuclear abnormality (NA) assay in fish has been widely applied for toxicity risk assessment under field and laboratory conditions. The zebrafish (Danio rerio) has become a suitable model system for assessing the NA induced by pollutants. Thus, the current study aimed to summarize and discuss the literature concerning micronucleus (MN) and other NA in zebrafish and its applications in toxicity screening and environmental risk assessment. The data concerning the publication year...
#1Jean-Michel RabanelH-Index: 14
#2Jimmy FaivreH-Index: 8
Last. Charles RamassamyH-Index: 32
view all 0 authors...
The field of nanomedicine has significantly influenced research areas such as drug delivery, diagnostics, theranostics, and regenerative medicine; however, the further development of this field will face significant challenges at the regulatory level if related guidance remains unclear and unconsolidated. This review describes those features and pathways crucial to the clinical translation of nanomedicine and highlights considerations for early-stage product development. These include identifyin...
New nanoparticles and biomaterials are increasingly being used in biomedical research for drug delivery, diagnostic applications, or vaccines, and they are also present in numerous commercial products, in the environment and workplaces. Thus, the evaluation of the safety and possible therapeutic application of these nanomaterials has become of foremost importance for the proper progress of nanotechnology. Due to economical and ethical issues, in vitro and in vivo methods are encouraged for the t...
#1Mengqi Sun (Capital Medical University)H-Index: 2
#1Hung-Chieh Lee (Mackay Medical College)H-Index: 11
#2Cheng-Yung Lin (Mackay Medical College)H-Index: 4
Last. Huai-Jen Tsai (Mackay Medical College)H-Index: 31
view all 3 authors...
The nearly simultaneous convergence of human genetics and advanced molecular technologies has led to an improved understanding of human diseases. At the same time, the demand for drug screening and gene function identification has also increased, albeit time- and labor-intensive. However, bridging the gap between in vitro evidence from cell lines and in vivo evidence, the lower vertebrate zebrafish possesses many advantages over higher vertebrates, such as low maintenance, high fecundity, light-...
#2Carlha Gutiérrez-Lovera (University of Santiago de Compostela)H-Index: 3
view all 11 authors...
Triple negative breast cancer (TNBC) is known for being very aggressive, heterogeneous and highly metastatic. The standard of care treatment is still chemotherapy, with adjacent toxicity and low efficacy, highlighting the need for alternative and more effective therapeutic strategies. Edelfosine, an alkyl-lysophospholipid, has proved to be a promising therapy for several cancer types, upon delivery in lipid nanoparticles. Therefore, the objective of this work was to explore the potential of edel...
#1Nisha Chander (UBC: University of British Columbia)
#2Johannes Morstein (NYU: New York University)H-Index: 9
Last. Dominik Witzigmann (UBC: University of British Columbia)H-Index: 16
view all 7 authors...
Encapsulation of small molecule drugs in long-circulating lipid nanoparticles (LNPs) can reduce toxic side effects and enhance accumulation at tumor sites. A fundamental problem, however, is the slow release of encapsulated drugs from these liposomal systems at the disease site resulting in limited therapeutic benefit. Methods to trigger release at specific sites are highly warranted. Here, it is demonstrated that incorporation of ultraviolet (UV-A) or red-light photoswitchable-phosphatidylcholi...
1 CitationsSource
#1Flavia FontanaH-Index: 18
Last. Hélder A. SantosH-Index: 69
view all 4 authors...
In vivo models remain a principle screening tool in the drug discovery pipeline. Here, the challenges associated with the need for animal experiments, as well as their impact on research, individual/societal, and economic contexts are discussed. A number of alternatives that, with further development, optimization, and investment, may replace animal experiments are also revised.
2 CitationsSource
#1Anna Pratsinis (University of Basel)
#2Philipp Uhl (University Hospital Heidelberg)H-Index: 7
Last. Jörg Huwyler (University of Basel)H-Index: 49
view all 9 authors...
Recently, a lipopeptide derived from the hepatitis B virus (HBV) large surface protein has been developed as an HBV entry inhibitor. This lipopeptide, called MyrcludexB (MyrB), selectively binds to the sodium taurocholate cotransporting polypeptide (NTCP) on the basolateral membrane of hepatocytes. Here, the feasibility of coupling therapeutic enzymes to MyrB was investigated for the development of enzyme delivery strategies. Hepatotropic targeting shall enable enzyme prodrug therapies and detox...